The Eli Lilly and Novo Nordisk logos.
Mike Blake | Tom Little | Reuters
Each time Novo urges buyers to look forward, Eli Lilly offers them one more reason to look again at its widening lead over the Danish drugmaker.
Novo this week laid out an formidable technique to reignite development past its top-selling Wegovy and Ozempic injections, which face patent expirations in key markets within the early 2030s. At its Capital Markets Day on Monday, the corporate promised a pipeline of potential blockbuster merchandise, together with medication that might diversify from its core space of weight problems and diabetes.
However Wall Avenue up to now is not satisfied by Novo’s highway map. Traders pummeled the drugmaker’s inventory, underwhelmed by development targets that matched business averages slightly than outpacing them. They have been additionally skeptical of the dearth of readability round a near-term turnaround plan.
On the similar time, Lilly continues to chip away at its rival’s market share — together with within the burgeoning weight problems capsule area.
Novo hopes to maintain its early lead within the oral weight reduction market after the profitable launch of the Wegovy capsule, months forward of Lilly’s rival capsule, Foundayo. Novo CEO Mike Doustdar informed CNBC on Tuesday that early adoption suggests sufferers might have been ready for a substitute for injections.
“If that continues to the extent that we have now seen, then sure, mathematically, by the top of the last decade, there’s going to be a bigger portion on the capsule than injectable,” he stated.
However Lilly is sizzling on its heels, backed by its business firepower.
In an unique interview with CNBC on Monday, Lilly CEO Dave Ricks stated the drugmaker’s new weight problems capsule, Foundayo, is slowly gaining floor within the U.S. One-third of latest GLP-1 capsule sufferers are taking Lilly’s drug, and its share of that oral market is rising “week by week,” Ricks informed CNBC in Houston, Texas.
Lilly can also be claiming an early lead within the newly established Medicare marketplace for weight problems medication, after the federal program began protecting these therapies in July. Ricks stated 700,000 seniors have began GLP-1s in Medicare following the beginning of protection, and 70% of these sufferers are on Lilly’s medication.
He added that Medicare sufferers have proven a specific desire for Lilly’s weight problems injection Zepbound, which has helped the corporate change into the dominant participant within the broader market. Lilly stated in August that it held a couple of 61% share within the U.S. GLP-1 area within the second quarter, whereas Novo held roughly 39%.
Whereas buyers appeared to need extra element on Novo’s plans for post-Wegovy and Ozempic development at Monday’s investor occasion, the drugmaker is betting that there could possibly be a couple of successor to the mega-blockbuster franchise.
For Novo, the problem is just not solely changing income from Wegovy and Ozempic once they lose exclusivity and face extra generic competitors. It’s convincing buyers that the corporate can regain momentum in a GLP-1 promote it helped set up years earlier than Lilly got here into the image, at the same time as its rival continues to construct its lead.
Lilly more likely to maintain its higher hand
Whilst Novo works to show itself round after two bruising years marked by a number of setbacks, analysts say Lilly has a number of benefits that would assist it keep its spot on the high of the weight problems drug market.
“Lilly is within the management place, and we predict that they’ll stay on this robust management place, given their substantial business benefit, their international initiative to globalize their merchandise additional, after which their superior pipeline of novel candidates as properly,” Leerink Companions analyst David Risinger stated in an interview.
Risinger expects Foundayo’s share of the oral GLP-1 market to proceed rising, pointing to Lilly’s “great business firepower” and higher spending capability to advertise the drug. However Risinger expects Foundayo to ultimately dominate the capsule market globally, partially as a result of it ought to be more cost effective to fabricate at scale than the Wegovy capsule.
Foundayo is a small-molecule drug, which could be manufactured in a different way and extra simply at scale than peptide medication resembling Novo’s Wegovy capsule and current injectable GLP-1s. Whereas Foundayo results in much less weight reduction on common than the Wegovy capsule, it does not carry any meals and water restrictions, which could possibly be a promoting level for some sufferers.
Novo executives this week didn’t immediately reply questions on whether or not Foundayo is simpler to fabricate and scale. Novo is investing billions in manufacturing services and, executives stated this week, the corporate goals to have the ability to improve the variety of sufferers on its GLP-1 medication tenfold by 2030. Executives have repeatedly stated provide is just not a difficulty and that Novo is not going to face the identical shortages it did with injectable variations within the earlier days of Ozempic and Wegovy.
For Lilly, Zepbound’s increased efficacy than the unique doses of Wegovy has additionally been key to securing its market share lead over Novo within the injectable area. Novo has sought to slender that efficacy hole with a higher-dose model of Wegovy launched this yr, which ends up in roughly comparable weight reduction as Zepbound.
However Lilly is just not standing nonetheless.
The corporate has a pipeline of next-generation weight problems medication that would prolong its lead past Zepbound and Foundayo, Risinger stated. That features retatrutide, a triple-agonist that targets three intestine hormones and has produced higher weight reduction than current weight problems medication in scientific trials. Lilly plans to hunt approval for the drug within the first quarter of 2027.
Lilly can also be creating a weekly injection that targets the amylin receptor, a pathway concerned in urge for food and satiety that differs from these focused by current therapies. Risinger stated the drug has “a lot higher potential than the Avenue at the moment realizes,” significantly as a result of a big inhabitants of sufferers doesn’t tolerate or reply adequately to GLP-1 medication.
“We’re fairly enthusiastic concerning the firm’s pipeline for follow-on brokers past Zepbound and Foundayo,” Risinger stated.
Whereas buyers have been laser-focused on the headline weight reduction variety of Novo and Lilly’s next-generation medication, Novo sees a fragmented market forward.
Chief Scientific Officer Martin Holst Lange informed CNBC this week that the breadth of Novo’s future pipeline would give physicians and sufferers extra choices and improve uptake. The corporate is learning the impact of latest medication on components like tolerability, muscle preservation, their impact on obesity-linked situations, comfort and extra.
“We will not try this with one single drug,” Lange stated.
Novo bets on its subsequent technology
Mike Doustdar, left, CEO of Novo Nordisk, and David Ricks, CEO of Eli Lilly, hear as President Donald Trump speaks within the Oval Workplace throughout an occasion about weight reduction medication on Nov. 6, 2025.
Andrew Caballero-Reynolds | Afp | Getty Pictures
For Novo, the reply to Lilly’s dominance is a sweeping wager on what comes subsequent.
Novo is focusing on the launch of greater than 5 potential multi-blockbuster medication by 2030 and greater than 150 billion Danish kroner, or about $23 billion, in pipeline gross sales by 2035. It additionally plans to have no less than 5 Section 3 packages in weight problems and diabetes and one other 5 throughout different therapeutic areas, because it tries to diversify its pipeline.
The size of that plan highlights the issue Novo is making an attempt to resolve. It has patent safety on semaglutide, the energetic ingredient in Wegovy and Ozempic, till 2032. These two medication account for roughly two-thirds of Novo’s gross sales, racking up mixed gross sales of $31 billion in 2025.
Novo must persuade buyers that its pipeline of latest medication can fill the outlet when generic rivals enter the market. To this point, it hasn’t been in a position to shake off a multiyear inventory selloff after a sequence of setbacks.
The brand new lineup the corporate is banking on contains CagriSema, Novo’s mixture of semaglutide and a drug known as cagrilintide that targets amylin, which is predicted to launch early subsequent yr. That might be adopted by standalone cagrilintide and a higher-dose model of CagriSema in 2028, amongst different new weight problems merchandise. Wall Avenue is not significantly enthusiastic about CagriSema, whose earlier late-stage scientific trials upset buyers as a result of the drug confirmed weight reduction efficacy under expectations.
Novo, nevertheless, maintains CagriSema is efficient and differentiated sufficient to be commercially viable. Lange informed CNBC individualized doses would be the method ahead for the corporate’s subsequent massive wager and highlighted new late-stage knowledge launched this week. It confirmed CagriSema produced higher weight reduction than tirzepatide — the energetic ingredient in Zepbound and Lilly’s Mounjaro — in a head-to-head trial amongst folks with Kind 2 diabetes.
However these outcomes got here with caveats: The examine used decrease doses of the 2 medication, and tirzepatide beforehand outperformed CagriSema in a separate head-to-head Section 3 trial utilizing increased doses of each therapies.
In the meantime, Novo continues to be betting on the expansion of the weight problems capsule market.
Novo believes market share is not the one measure of success buyers ought to take a look at going ahead. The sheer quantity issues too, Doustdar informed CNBC, highlighting that the weight problems market can nonetheless develop considerably.
Novo plans to scale manufacturing capability sufficient to serve 15 million folks taking oral weight problems therapies by 2030, and has stated tablets may finally account for as a lot as half of the worldwide weight problems drug market. The corporate says its Wegovy capsule has already reached 7 million U.S. prescriptions, with 90% of these gross sales coming by cash-pay channels.
The issue is that buyers look like demanding greater than a promising pipeline.
Analysts on Monday pressed Novo executives on their pricing assumptions, questioning whether or not the corporate’s subsequent pipeline of medication can maintain premium worth factors as soon as Wegovy and Ozempic lose exclusivity.
Novo’s 2026 to 2030 income outlook additionally targets development in keeping with its pharmaceutical friends, slightly than a return to the outsized development from when Wegovy and Ozempic first boomed.
That leaves Novo with a troublesome balancing act. It has to defend its current weight problems franchise in opposition to Lilly whereas concurrently investing within the medication which can be supposed to exchange it.